stockrow
Friday 6 November 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
Lisata Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $170,000.00, down 83.0% from fiscal 2024.
- Revenue
- −98.3%
- EPS
- +40.7%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
1.02
0.03
+3.03%
Follow LSTA
Alert me
Lisata Therapeutics, Inc. (LSTA) P/E ratio
Lisata Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 3.4× (July 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2016 | 0.0× | — |
| Dec 2015 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.4×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| LSTA Lisata Therapeutics, Inc. | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| ICU SeaStar Medical Holding Corporation compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.1× |
| PTN Palatin Technologies, Inc. compare | 13.6× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)